

Sussex Research

BRD4-mediated repression of p53 is a target for combination therapy in AML

Anne-Louise Latif, Ashley Newcombe, Sha Li, Kathryn Gilroy, Neil A Robertson, Xue Lei, Helen Stewart, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Timothy Chevassut, others

Publication date

11-01-2021

Licence

This work is made available under the CC BY 4.0 licence and should only be used in accordance with that licence. For more information on the specific terms, consult the repository record for this item.

Document Version

Published version

Citation for this work (American Psychological Association 7th edition)

Latif, A.-L., Newcombe, A., Li, S., Gilroy, K., Robertson, N. A., Lei, X., Stewart, H., Cole, J., Terradas, M. T., Rishi, L., McGarry, L., McKeeve, C., Reid, C., Clark, W., Chevassut, T., & others, . (2021). *BRD4-mediated repression of p53 is a target for combination therapy in AML* (Version 2). University of Sussex. https://hdl.handle.net/10779/uos.23479328.v2

Published in

Nature Communications

Link to external publisher version

https://doi.org/10.1038/s41467-020-20378-8

Copyright and reuse:

This work was downloaded from Sussex Research Open (SRO). This document is made available in line with publisher policy and may differ from the published version. Please cite the published version where possible. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners unless otherwise stated. For more information on this work, SRO or to report an issue, you can contact the repository administrators at sro@sussex.ac.uk. Discover more of the University's research at https://sussex.figshare.com/









